Meyers JD, Flournoy N, Thomas ED. Nonbacterial pneumonia after allogeneic marrow transplantation: a review of ten years’ experience. Rev Infect Dis. 1982;4(6):1119–32.

Article  CAS  PubMed  Google Scholar 

Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis. 1986;153(3):478–88.

Article  CAS  PubMed  Google Scholar 

Ljungman P, Brand R, Hoek J, et al. Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European Group for Blood and Marrow Transplantation. Clin Infect Dis. 2014;59(4):473–81.

Article  PubMed  Google Scholar 

Teira P, Battiwalla M, Ramanathan M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016;127(20):2427–38.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Borst EM, Kleine-Albers J, Gabaev I, et al. The human cytomegalovirus UL51 protein is essential for viral genome cleavage-packaging and interacts with the terminase subunits pUL56 and pUL89. J Virol. 2013;87(3):1720–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goldner T, Hewlett G, Ettischer N, et al. The novel anticytomegalovirus compound AIC246 (letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol. 2011;85(20):10884–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chemaly RF, Ullmann AJ, Ehninger G. CMV prophylaxis in hematopoietic-cell transplantation. N Engl J Med. 2014;371(6):576–7.

Article  CAS  PubMed  Google Scholar 

Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377(25):2433–44.

Article  CAS  PubMed  Google Scholar 

Ljungman P, de la Camara R, Robin C, et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19(8):e260–72.

Article  PubMed  Google Scholar 

Hakki M, Aitken SL, Danziger-Isakov L, et al. American Society for Transplantation and Cellular Therapy Series: #3-prevention of cytomegalovirus infection and disease after hematopoietic cell transplantation. Transplant Cell Ther. 2021;27(9):707–19.

Article  PubMed  Google Scholar 

Chen K, Cheng MP, Hammond SP, et al. Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation. Blood Adv. 2018;2(16):2159–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

US FDA. Prevymis (letermovir) [package insert].

Kropeit D, McCormick D, Erb-Zohar K, et al. Pharmacokinetics and safety of the anti-human cytomegalovirus drug letermovir in subjects with hepatic impairment. Br J Clin Pharmacol. 2017;83(12):2678–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saullo JL, Miller RA. Cytomegalovirus therapy: role of letermovir in prophylaxis and treatment in transplant recipients. Annu Rev Med. 2023;74:89–105.

Article  CAS  PubMed  Google Scholar 

EMA. Prevymis (letermovir) [package insert].

Ljungman P, Schmitt M, Marty FM, et al. A mortality analysis of letermovir prophylaxis for cytomegalovirus (CMV) in CMV-seropositive recipients of allogeneic hematopoietic cell transplantation. Clin Infect Dis. 2020;70(8):1525–33.

Article  CAS  PubMed  Google Scholar 

Sassine J, Khawaja F, Shigle TL, et al. Refractory and resistant cytomegalovirus after hematopoietic cell transplant in the letermovir primary prophylaxis era. Clin Infect Dis. 2021;73(8):1346–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zamora D, Duke ER, Xie H, et al. Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation. Blood. 2021;138(1):34–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Russo D, Schmitt M, Pilorge S, et al. Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2024;11(2):e127–35.

Marty FM, Ljungman PT, Chemaly RF, et al. Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation. Am J Transplant. 2020;20(6):1703–11.

Article  CAS  PubMed  Google Scholar 

Shigle TL, Handy VW, Chemaly RF. Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant. Ther Adv Hematol. 2020;11:2040620720937150.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martino M, Pitino A, Gori M, et al. Letermovir prophylaxis for cytomegalovirus infection in allogeneic stem cell transplantation: a real-world experience. Front Oncol. 2021;11: 740079.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Limaye AP, Budde K, Humar A, et al. Letermovir vs valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients: a randomized clinical trial. JAMA. 2023;330(1):33–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Solano C, Giménez E, Albert E, et al. Immunovirology of cytomegalovirus infection in allogeneic stem cell transplant recipients undergoing prophylaxis with letermovir: a narrative review. J Med Virol. 2023;95(8): e29005.

Article  CAS  PubMed  Google Scholar 

Cassaniti I, Colombo AA, Bernasconi P, et al. Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection. Am J Transplant. 2021;21(4):1622–8.

Article  CAS  PubMed  Google Scholar 

Giménez E, Guerreiro M, Torres I, et al. Features of cytomegalovirus DNAemia and virus-specific T-cell responses in allogeneic hematopoietic stem-cell transplant recipients during prophylaxis with letermovir. Transpl Infect Dis. 2023;25(2): e14021.

Article  PubMed  Google Scholar 

Chavaz L, Royston L, Masouridi-Levrat S, et al. CMV infection after letermovir primary prophylaxis discontinuation in allogeneic hematopoietic cell transplant recipients. Open Forum Infect Dis. 2023;10(4): ofad169.

Article  PubMed  PubMed Central  Google Scholar 

Royston L, Royston E, Masouridi-Levrat S, et al. Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high-risk hematopoietic cell transplant recipients. Immun Inflamm Dis. 2021;9(3):771–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Studer U, Khanna N, Leuzinger K, et al. Incidence of CMV replication and the role of letermovir primary/secondary prophylaxis in the early phase after allogeneic hematopoietic stem cell transplantation: a single centre study. Anticancer Res. 2020;40(10):5909–17.

Article  CAS  PubMed  Google Scholar 

Robin C, Thiebaut A, Alain S, et al. Letermovir for secondary prophylaxis of cytomegalovirus infection and disease after allogeneic hematopoietic cell transplantation: results from the French Compassionate Program. Biol Blood Marrow Transplant. 2020;26(5):978–84.

Article  CAS  PubMed  Google Scholar 

Lin A, Maloy M, Su Y, et al. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: real-world experience. Transpl Infect Dis. 2019;21(6): e13187.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pérez AB, Santos Bravo M, Vidal-Verdú E, et al. Real-life experience in two cases of secondary prophylaxis with letermovir for CMV infection in solid organ transplantation. Microbiol Spectr. 2023;11(6): e0163023.

Article